Simulation of the reversal of neuromuscular block by sequestration of the free molecules of the muscle relaxant.

J Pharmacokinet Pharmacodyn

Department of Anesthesiology, College of Medicine, University of Toledo, 3000 Arlington Avenue, Toledo, OH 43614-2598, USA.

Published: December 2007

The study examined in simulations the interaction between a muscle relaxant and an antagonist that binds the free molecules of the relaxant, as experimentally demonstrated for rocuronium and sugammadex. The hypothetical muscle relaxant D and the hypothetical antagonist X were assigned pharmacokinetic properties to define the time course of their concentrations in plasma, and pharmacodynamic properties to define binding of D to either X or the receptors at the motor end plates. D, X, and their complex DX were postulated to diffuse between plasma and the effect compartment. The first and the fourth twitch elicited in sequential trains of four stimuli were evaluated in a model of neuromuscular transmission. The rates of reactions were formulated as differential equations and the equations solved numerically. If the affinity of D for X is comparable to that of D for the postsynaptic receptors, doses of X two to four times larger than the dose of D produce a fast and a complete recovery of the twitches. Smaller doses of X or lower affinities of D for X accomplish a slower and only partial recovery. Additionally, the complete restoration of twitch strength within 2 min after the injection of X requires that X and DX diffuse into the effect compartment. The simulations reveal the physicochemical, pharmacokinetic, and pharmacodynamic properties of an antagonist that restores twitch strength by sequestering the free molecules of the muscle relaxant.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10928-007-9068-yDOI Listing

Publication Analysis

Top Keywords

muscle relaxant
16
free molecules
12
molecules muscle
8
properties define
8
pharmacodynamic properties
8
twitch strength
8
relaxant
5
simulation reversal
4
reversal neuromuscular
4
neuromuscular block
4

Similar Publications

Beta - stimulant, that is, β - adrenergic stimulant, also known as β - agonists, is bioactive catecholamine compounds naturally produced in animals' adrenal medulla glands that induce relaxation in asthmatic airway smooth muscles upon inhalation while also temporarily boosting athletic alertness and alleviating fatigue. However, their potential for dependency poses health risks including unnoticed exacerbation leading to severe illness or fatality prompting their inclusion on WADA's prohibited substances list. Surface - enhanced Raman spectroscopy (SERS) offers a rapid, sensitive, and label - free means for identifying characteristic peaks associated with β - agonist compounds.

View Article and Find Full Text PDF

Background: Subarachnoid anesthesia is the primary anesthetic method for elective cesarean section surgery, characterized by rapidly taking effect and reliable analgesia. However, subarachnoid anesthesia is prone to cause a high block level, resulting in a high incidence of maternal hypotension. How to reduce the incidence of maternal hypotension under subarachnoid anesthesia is a practical problem that needs to be solved urgently in clinical practice.

View Article and Find Full Text PDF

Background: Motor imagery is the mental representation of a movement without physical execution. When motor imagery is performed to enhance motor learning and performance, participants must reach a temporal congruence between the imagined and actual movement execution. Identifying factors that can influence this capacity could enhance the effectiveness of motor imagery programs.

View Article and Find Full Text PDF

Vascular smooth muscle cell (SMC) relaxation by guanylyl cyclases (GCs) and cGMP is mediated by NO and its receptor soluble GC (sGC) or natriuretic peptides (NPs) ANP/BNP and CNP with the receptors GC-A and GC-B, respectively. It is commonly accepted that cultured SMCs differ from those in intact vessels. Nevertheless, cell culture often remains the first step for signaling investigations and drug testing.

View Article and Find Full Text PDF

Potential beneficial impacts of tadalafil on cardiovascular diseases.

J Chin Med Assoc

January 2025

Department and Institute of Pharmacology, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC.

Tadalafil is a selective phosphodiesterase type 5 (PDE5) inhibitor commonly used for the treatment of erectile dysfunction and benign prostatic hyperplasia. Its mechanism of action involves the inhibition of PDE5, leading to increased levels of nitric oxide and cyclic guanosine monophosphate in the corpus cavernosum, which facilitates smooth muscle relaxation. This article reviews studies using tadalafil in the treatment of cardiovascular diseases and emphasizes its potential advantages in conditions such as pulmonary arterial hypertension, atherosclerosis, coronary artery disease, myocardial infarction, heart failure, stroke, diabetic ulcers, and cardiomyopathy.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!